Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 696

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 6
Chunk 696
---
 Total
    lease cost 
    $5,092  
    $511,409 

    F-14

MIRA
                                            PHARMACEUTICALS, INC.

NOTES
TO THE FINANCIAL STATEMENTS

DECEMBER
31, 2024 AND 2023

Supplemental
cash flow information related to leases were as follows:

 Schedule
of Cash Flow Information Related to Leases

    2024  
    2023 

    Year
    Ended December 31, 

    2024  
    2023 
  
    Other
    lease information 

    Cash paid for amounts
    included in the measurement of lease liabilities 

    Operating
    cash flows from operating leases 
    $5,092  
    $511,409 

Note
7. Income taxes:

The
significant components of the Company’s net deferred tax assets are as follows as of December 31:

 Schedule
of Deferred Tax Assets and Liabilities

    2024  
    2023 

    December
    31, 

    2024  
    2023 
  
    Deferred
    tax assets 

    Net
    operating loss carry-forward 
    $4,555,400  
    $2,430,529 
  
    Section
    174 Qualified Research Expenditures 
     1,232,033  
     533,159 
  
    Stock
    compensation 
     1,099,090  
     650,018 
  
    ROU
    liability 
     -  
     1,291 
  
    R&D
    Credit 
     38,640  
     - 
  
    Other 
     -  
     204 
  
    Deferred
    tax assets, Gross 
     6,925,163  
     3,615,201 
  
    Less:
    valuation allowance 
     (6,925,163) 
     (3,613,901)
  
    Deferred
tax assets, Net 
     -  
     1,291 
  
    Deferred
    tax liabilities 

    ROU
    asset 
     -  
     (1,291)
  
    Total
    net deferred tax asset 
    $-  
     - 

Beginning
in 2022, in accordance with Internal